Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma

BACKGROUND: Vorolanib (X-82, CM082) is a multi-target tyrosine kinase inhibitor. This study aimed to evaluate the tolerability, safety, pharmacokinetics and antitumor activities of vorolanib plus everolimus (an inhibitor of mammalian target of rapamycin). METHODS: Patients had histologically or cyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Xinan, Yan, Xieqiao, Chi, Zhihong, Cui, Chuanliang, Si, Lu, Tang, Bixia, Li, Siming, Mao, Lili, Lian, Bin, Wang, Xuan, Bai, Xue, Zhou, Li, Kong, Yan, Dai, Jie, Ding, Lieming, Mao, Li, Guo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184160/
https://www.ncbi.nlm.nih.gov/pubmed/32335374
http://dx.doi.org/10.1016/j.ebiom.2020.102755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184160/
https://www.ncbi.nlm.nih.gov/pubmed/32335374
http://dx.doi.org/10.1016/j.ebiom.2020.102755

Ejemplares similares